Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control and Announces First Subjects Dosed in Phase 1 DISARM ...

The preclinical pharmacokinetic (PK) and pharmacodynamic (PD) studies, conducted in cynomolgus monkeys following subcutaneous and intravenous administration, demonstrated rapid downregulation of the ...

FDA approves Novo Nordisk's Sogroya(R) as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...
The Manila Times

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery comp ...
Medical Dialogues

Fremanezumab Reduces Migraine Days in Children and Adolescents: NEJM

A new study published in The New England Journal of Medicine showed that Fremanezumab reduced migraine and headache days more than a placebo in children and adolescents with episodic migraine.
PharmiWeb

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisApproval in adults and children aged 6 years and older supported by phase 3 study ...
Pharmabiz

US FDA approves Sanofi and Regeneron’s Dupixent for allergic fungal rhinosinusitis

US FDA approves Sanofi and Regeneron’s Dupixent for allergic fungal rhinosinusitis: Paris Thursday, February 26, 2026, 15:00 Hrs [IST] The US Food and Drug Administration (FDA) ...
Medical Dialogues

Rezpegaldesleukin Shows Sustained Benefit in Moderate-to-Severe Atopic Dermatitis in Phase 2 b trial

The phase 2b REZOLVE-AD trial enrolled 393 adults with moderate-to-severe atopic dermatitis across approximately 110 global ...

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing

VH184, the first, third‑generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals Additional in-vitro data on VH184 demonstrate improved potency and an ...

Sanofi: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study ...
PharmiWeb

CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel

SOUTH SAN FRANCISCO, CA / ACCESS Newswire / February 25, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential ...